Noroxymorphone

Noroxymorphone is an opioid[1] which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of narcotic antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity.[2][3][1]

Noroxymorphone
Clinical data
Routes of
administration
intravenous, intramusucular, subcutaneous, oral, rectal, intranasal
Legal status
Legal status
Identifiers
  • 7,8-Dihydro-14-hydroxynormorphinone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.046.859
Chemical and physical data
FormulaC16H17NO4
Molar mass287.315 g·mol−1
3D model (JSmol)
  • Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O
  • InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1
  • Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637 and in 2014 the DEA set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale.[4] In other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.

See also

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.